Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Non-Current Deferred Tax Liability (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $552000.0 for Q4 2024.

  • For Q4 2024, Non-Current Deferred Tax Liability rose 32.69% year-over-year to $552000.0; the TTM value through Nov 2024 reached $552000.0, up 32.69%, while the annual FY2024 figure was $543000.0, 96.19% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2024 was $552000.0 at Lifecore Biomedical, Inc. \De\, up from $443000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $36.5 million in Q2 2021 and troughed at $10000.0 in Q4 2022.
  • A 5-year average of $5.3 million and a median of $701500.0 in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: crashed 99.65% in 2022 and later soared 11197.62% in 2023.
  • Year by year, Non-Current Deferred Tax Liability stood at $6.6 million in 2020, then plummeted by 81.89% to $1.2 million in 2021, then crashed by 99.17% to $10000.0 in 2022, then skyrocketed by 4060.0% to $416000.0 in 2023, then surged by 32.69% to $552000.0 in 2024.
  • Business Quant data shows Non-Current Deferred Tax Liability for LFCR at $552000.0 in Q4 2024, $443000.0 in Q3 2024, and $543000.0 in Q2 2024.